Evidence map›Paper›PMID 42109806›Full record

ArticleEFSA journal. European Food Safety Authority2015

Scientific Opinion on an application (EFSA-GMO-NL-2010-80) for the placing on the market of herbicide-tolerant genetically modified maize NK603 × T25 for food and feed uses, import and processing under Regulation (EC) No 1829/2003 from Monsanto.

EFSA Panel on Genetically Modified Organisms (GMO)

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

EFSA Panel on Genetically Modified Organisms (GMO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single events NK603 and T25 were combined to produce the stack two-event maize NK603 × T25. The EFSA GMO Panel previously assessed the two single events and did not identify safety concerns in the context of their scope. No new data on single maize events leading to a modification of the original conclusions on their safety were identified. Agronomic and phenotypic characteristics, as well as compositional data of maize NK603 × T25, did not give rise to food/feed and environmental safety concerns. The EFSA GMO Panel considers that there is no reason to expect interactions between the single events that could impact on the food and feed safety and the nutritional properties of maize NK603 × T25. There are no indications of an increased likelihood of establishment and spread of feral maize plants. Considering the scope of application EFSA-GMO-NL-2010-80, potential interactions with the biotic and abiotic environment were not considered to be a relevant issue. The unlikely but theoretically possible transfer of the recombinant genes from maize NK603 × T25 to environmental bacteria does not give rise to any safety concern. The post-market environmental monitoring plan and reporting intervals are in line with the scope. In conclusion, the EFSA GMO Panel considers that the information available for maize NK603 × T25 addresses the scientific comments raised by Member States and that maize NK603 × T25, as described in this application, is as safe as its non-GM comparator and non-GM conventional maize varieties with respect to potential effects on human and animal health and the environment in the context of its scope.

Indexed as

CP4 EPSPSGMOherbicide tolerantmaize (Zea mays)PATstack

Identifiers

PMID42109806
PMCPMC13151584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.